|Dr. John M. Maraganore||CEO & Exec. Director||2.07M||17.34M||1963|
|Dr. Yvonne L. Greenstreet M.B.A., MBChB, MBA||Pres & COO||1.24M||10.1M||1963|
|Mr. Jeffrey V. Poulton M.B.A.||CFO & Exec. VP||893.47k||N/A||1968|
|Ms. Laurie Bartlett Keating J.D.||Exec. VP, Chief Legal Officer & Sec.||835.16k||6.77M||1954|
|Dr. Akshay K. Vaishnaw||Pres of R&D||1.09M||4.23M||1963|
|Dr. Alfred W. Boyle Ph.D.||Chief Technical Operations & Quality Officer||N/A||N/A||N/A|
|Dr. Kevin Fitzgerald||Sr. VP & Chief Scientific Officer||N/A||N/A||N/A|
|Ms. Christine Regan Lindenboom||Sr. VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Ms. Agnieszka Gallagher J.D.||Chief Ethics & Compliance Officer||N/A||N/A||N/A|
|Mr. Mark Baglin||VP of Global Marketing||N/A||N/A||N/A|
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; lumasiran for the treatment of advanced PH1 and recurrent renal stones; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG to develop, manufacture, and commercialize RNAi therapeutics for the treatment of proprotein convertase subtilisin/kexin type 9, hypercholesterolemia, and other human diseases; with Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics to treat SARS-CoV-2, the virus that causes the disease COVID-19; Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational RNAi therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease; and with Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Alnylam Pharmaceuticals, Inc.’s ISS Governance QualityScore as of June 1, 2021 is 7. The pillar scores are Audit: 3; Board: 4; Shareholder Rights: 6; Compensation: 10.